Register for our free email digests:
US Election 2016
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
CDER Director's' video advises focusing on the work and "keeping our heads down."
Latest From US Election 2016 & BioPharmaceutical
President Trump is empty-handed on health care victories so far, as initial health reform repeal efforts collapsed and the shock value of drug pricing tweets wore off. But some actions may evolve into biopharma impact further down the road.
Trump-watchers, check out our new podcast covering Trump's first months in office and the full GOP policy agenda. (Free with registration.)
Although signs suggest the Trump Administration is moving back to the establishment center, biopharma’s knowledge elites remain in the populists’ crosshairs. It’s vital to change the narrative on medicines and markets. In this brief opinion piece In Vivo provides seven ways for the C-suite to do just that.
The pharmaceutical industry is always struggling to get good press when it comes to drug prices. But a recent headline in Breitbart News is one to savor – as long as the President believes it.
Brand name industry’s image campaign promises to 'Go Boldly' – but there has been nothing bold about its public response to the Trump Administration’s efforts to repeal the Affordable Care Act, the President’s strong words on drug pricing, or even proposed cuts to NIH funding and FDA. Treading carefully makes a lot of sense – but is there a line that PhRMA won’t let the Administration cross?
When it comes to drug pricing, one size certainly doesn’t fit all. Biopharma firms need to devise and design appropriate pricing and commercial strategies for payers, a group of customers that don’t all care about the same things and, in some cases, whose needs may be diametrically opposed.
Having sat on the sidelines during the unsuccessful effort to repeal and replace Obamacare, the pharma industry may find the rest of its legislative agenda, from taxes to even user fee reauthorization, could become more difficult.
Pfizer CEO Ian Read explains why industry has stayed on the sidelines during the current health reform debate and defends drug pricing practices during a speech to the National Press Club.
President's pledge to merge drug pricing control with a revamp of the Affordable Care Act wins applause at Kentucky rally, where the president reeled through a number of his populist issues, even as the idea makes scant legislative progress.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.